Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980818 | 1.00 | TSHR (0.63) | TSHRSMN1; SMN2HPGDLMNAKMT2A | |
| SCHEMBL5645688 | 0.88 | LMNA (0.62) | TSHRSMN1; SMN2HPGDLMNAKMT2A | |
| SCHEMBL17531157 | 0.86 | TSHR (0.49) | TSHRSMN1; SMN2HPGDLMNAKMT2A | |
| SCHEMBL22302827 | 0.82 | TSHR (0.46) | TSHRSMN1; SMN2HPGDLMNAKMT2A | |
| SCHEMBL10387449 | 0.82 | LMNA (0.68) | TSHRSMN1; SMN2HPGDLMNAKMT2A | |
| SCHEMBL25184403 | 0.82 | TSHR (0.47) | TSHRSMN1; SMN2LMNADYRK3CCNA2 | |
| SCHEMBL1515571 | 0.82 | NNMT (0.46) | TSHRSMN1; SMN2HPGDLMNADYRK3 | |
| SCHEMBL23188126 | 0.81 | TSHR (0.45) | TSHRSMN1; SMN2HPGDLMNAKMT2A | |
| SCHEMBL23188080 | 0.81 | TSHR (0.45) | TSHRSMN1; SMN2HPGDLMNAKMT2A | |
| SCHEMBL20381745 | 0.81 | HPGD (0.51) | TSHRSMN1; SMN2HPGDLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850082-B | Preparation method of 2-nitro-4-trifluoromethyl benzoic acid | 内蒙古蓝科生物科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250049966-A1 | SMALL MOLECULE TRACER FOR IMAGING ALPHA-SYNUCLEIN AGGREGATES | FUDAN UNIVERSITY (CN) | 2025-02-13 | — | — | US | disclosed |
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORP (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NEUROPN THERAPEUTICS (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240024313-A1 | BIARYL ETHER UREA COMPOUNDS | Jazz Pharmaceuticals Therapeutics, Inc. | 2024-01-25 | — | — | US | disclosed |
| WO-2023239629-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE CDK2 | Plexium, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-3730494-B1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD CONTROLLING AGENT CONTAINING SAME | SUMITOMO CHEMICAL CO (JP) | 2023-11-08 | — | — | EP | disclosed |
| US-20230232827-A1 | METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS RESISTANT TO QoI FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-07-27 | — | — | US | disclosed |
| WO-2023109745-A1 | SMALL-MOLECULE PROBE FOR IMAGING OF α-SYNUCLEIN AGGREGATE | 复旦大学 | 2023-06-22 | — | — | WO | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| CN-1918165-A | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | CN | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| CN-1882545-A | Substituted nicotinoylcarbamates as pesticides | BAYER CROPSCIENCE AG (DE) | 2006-12-20 | — | — | CN | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-6225320-B1 | TREATMENT OF PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTTHERPETIC NEURALGIA | MERCK SHARP & DOHME LTD. (GB) | 2001-05-01 | — | — | US | disclosed |
| EP-0989987-A1 | SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2000-04-05 | — | — | EP | disclosed |
| EP-0953566-A2 | Selective transformation of pyridines with electrophiles | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-03 | — | — | EP | disclosed |
| WO-1998054187-A1 | SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024313-A1 | BIARYL ETHER UREA COMPOUNDS | FAAH, FAAH2, FAH | TSHR 2607/4885SMN1; SMN2 2993/4885HPGD 969/4885 |
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | KRAS, NRAS, HRAS | TSHR 4532/4885SMN1; SMN2 3615/4885HPGD 448/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | TSHR 2392/4885SMN1; SMN2 4097/4885HPGD 836/4885 |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, HPGDS | TSHR 4531/4885SMN1; SMN2 3266/4885HPGD 43/4885 |
| US-20250049966-A1 | SMALL MOLECULE TRACER FOR IMAGING ALPHA-SYNUCLEIN AGGREGATES | SNCA, PARK7, GDI1 | TSHR 3073/4885SMN1; SMN2 873/4885HPGD 4322/4885 |
| US-20230232827-A1 | METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS RESISTANT TO QoI FUNGICIDES | CYC1, SQOR, MT-CO3 | TSHR 3023/4885SMN1; SMN2 4452/4885HPGD 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.